Followers | 101 |
Posts | 13186 |
Boards Moderated | 0 |
Alias Born | 06/01/2013 |
![](https://investorshub.advfn.com/uicon/401562.png?cb=1660063619)
Monday, May 10, 2021 11:17:37 AM
is FOS
It hasn't been done for Hiv, influenza yet, right ?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163683666
Why are rapid SARS-CoV-2 antigen tests not tested and certified before they are marketed, as is done with HIV tests?
Pursuant to the currently applicable EU Directive for in vitro diagnostic devices (IVD), tests for the human immunodeficiency virus (HIV) rank among the category of high risk products, and are therefore subject to the certification by a Notified Body. COVID-19 tests are currently still categorised as “low-risk IVDs”, and as such, can be certified by the manufacturers themselves. They do not require independent testing before they can be marketed. SARS-CoV-2 self tests are an exception to this. For these tests, it is required that a Notified Body reviews certain aspects or that the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) grants a special authorisation (see below).
The future IVD Directive, the implementation of which will be compulsory as from May 2022, requires an EU reference laboratory and a Notified Body to be consulted for the testing of SARS-CoV-2 tests. For this purpose, a laboratory assay and an independent verification of the data will be required for the tests.
The Paul-Ehrlich-Institut is preparing to apply for its role of one of the EU reference laboratories in order to review high risk tests in the laboratory.
The Paul-Ehrlich-Institut welcomes the classification of tests such as SARS-Co-2 antigen tests and their independent review und evaluation, as planned as from May 2022. This will increase the safety of and confidence in these in vitro diagnostic devices.
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM